NCT05190679Completed
Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 6 May 2026
Brief summary (registry, in English)
This is a prospective, case-control study that seeks to learn about the role of genetics in early onset atrial fibrillation (AF) and if genetic testing can be used to improve how the investigators treat atrial fibrillation. The study will enroll 225 participants. Eligible participants will have undergone sequencing for arrhythmia and cardiomyopathy (CM) genes. Based on those results, participants will be recruited for an outpatient research visit with testing that includes cardiac MRI, rest/stress/signal-averaged ECGs, and cardiac monitoring. If an inherited arrhythmia/CM syndrome is diagnosed, guideline-directed changes to medical care will be recommended.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 155 (actual)
- First submitted
- 28 Dec 2021
- Start date
- 27 Apr 2022
- Primary completion date
- 3 Mar 2026
- Lead sponsor
- Vanderbilt University Medical Center
- Diseases
- Atrial fibrillation
- NCT number
- NCT05190679
What you commit to
- Study type: Observational
- Participants enrolled: 155
- From 27 Apr 2022 to the primary completion date, 3 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- -Pregnant women
Who the study is looking for
- Minors \>15 years
- Adult \> 18 years
- Able to provide written informed consent
- Previously enrolled in the Vanderbilt Atrial Fibrillation Registry (IVR#020669)
- Atrial Fibrillation Ablation Registry (IRB#110881)
- Early-onset Atrial Fibrillation Registry (IRB#201666)
- Underwent whole genome sequencing/whole exome sequencing or clinical genetic testing and based on those results meets the genetic criteria for cases and controls as defined as a Cardiomyopathy (CM) Rare Variant (P/LP rare variant in CM gene, Arrhythmia Rare Variant (P/LP rare variant in arrhythmia gene), or a Control (no rare variant in CM, arrhythmia, or other Atrial Fibrillation gene).
- Diagnosis of Atrial Fibrillation prior to age of 65 (\</=65)
Age in the registry: 15 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vanderbilt University Medical Center Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.